All In Biotech

Drug Trial Radar · NCT01538966

Acromegaly Combination Treatment Study

Comparison of Combination Low-Dose SRL + Daily Pegvisomant Therapy, Low-Dose SRL + Weekly Pegvisomant Therapy, and High-Dose SRL + Weekly Pegvisomant Therapy

Last checked: Nov 20, 2026Latest source record: Jan 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

76

Actual

Start

Mar 29, 2012

Primary completion

May 20, 2022

Study completion May 20, 2022

Sponsor

Lead sponsor
Cedars-Sinai Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily pegvisomant will attain equivalent control of serum insulin-like growth factor (IGF)-1 levels at a lower cost, compared to combination high dose SRL and weekly pegvisomant. Lower doses of therapy will greatly reduce cost of acromegaly therapy.

Conditions

  • Acromegaly

Interventions

  • PegvisomantDrug

  • Octreotide LARDrug

  • LanreotideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cost EffectivenessTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.